Prognostic implications of HER2 heterogeneity in gastric cancer.

Motoshima, Shigenobu; Yonemoto, Koji; Kamei, Hideki; Morita, Michi; Yamaguchi, Rin

Motoshima, Shigenobu; Yonemoto, Koji; Kamei, Hideki; Morita, Michi; Yamaguchi, Rin.

Afiliação

Motoshima S; Biostatistics Center, Graduate School of Medicine, Kurume University, Kurume, Fukuoka, Japan.
Yonemoto K; Department of Clinical Laboratory, Kokura Medical Center, Kitakyushu, Fukuoka, Japan.
Kamei H; Advanced Medical Research Center, Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan.
Morita M; Department of Surgery, Japan Community Health Care Organization Kurume General Hospital, Kurume, Fukuoka, Japan.
Yamaguchi R; Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.

Oncotarget ; 9(10): 9262-9272, 2018 Feb 06.

Article em En | MEDLINE | ID: mdl-29507688

Palavras-chave

HER2; gastric cancer; intratumoral heterogeneity; prognosis; trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google